Phase II study of MGI-114 (NSC# 683863) administered intravenously for five days every 28 days to patients with metastatic colorectal cancer

Trial Profile

Phase II study of MGI-114 (NSC# 683863) administered intravenously for five days every 28 days to patients with metastatic colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2010

At a glance

  • Drugs Irofulven (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2010 Status changed from Active,not recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top